Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | UB-VV111 |
| Trade Name | |
| Synonyms | UB VV111|UBVV111 |
| Drug Descriptions |
UB-VV111 is a replication-defective lentiviral vector that transduces T-cells with a transgene containing a chimeric antigen receptor (CAR) targeting CD19 and a rapamycin-activated cytokine receptor, which potentially enhances expansion and persistence of transduced T-cells and induces antitumor activity (Blood (2024) 144 (Supplement 1): 2046; Blood (2024) 144 (Supplement 1): 1750.1). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C211928 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Sirolimus + UB-VV111 | Sirolimus UB-VV111 | 0 | 1 |
| UB-VV111 | UB-VV111 | 0 | 1 |